Pay in 4 interest-free payments of $7.18 Learn more
Ships within 48 hours · Estimated delivery Aug 28 - Sep 2
DOI: 10.3803/EnM.2025.2420
The SELECT safety analysis found breast cancer rates were marginally lower on semaglutide than placebo, and a 2025 meta-analysis of 50 randomised GLP-1 trials found no increased breast cancer risk
The largest human trial had only 16 test subjects, which means that if BPC-157 had, say, a 1% risk of a truly catastrophic side effect, a test like that would have a very small chance of catching it
Stark, clear, and high-purity
US$ 29.17
US$ 23.51
US$ 23.19
US$ 26.48
